

Effective Date: 7/1/2020
Last Reviewed: 4/2020, 3/2021, 2/2022
Scope: Medicaid

## **LATUDA (lurasidone oral tablet)**

### **POLICY**

#### **I. INDICATIONS**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

##### **Schizophrenia**

Latuda is indicated for the treatment of schizophrenia.

##### **Bipolar Disorder, Depressed Phase (Bipolar Depression)**

Latuda is indicated as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with Bipolar I Disorder.

All other indications are considered experimental/investigational and are not a covered benefit.

#### **II. CRITERIA FOR APPROVAL**

##### **A. Schizophrenia**

An authorization may be granted for 12 months when the following criteria (1) and (2) are met:

1. The patient experienced an inadequate treatment response after a trial of at least 30 days, intolerance, or contraindication to three generic atypical antipsychotics
2. The requested drug is being prescribed for the treatment of schizophrenia

##### **B. Bipolar Disorder, Depressed Phase (Bipolar Depression)**

An authorization may be granted for 12 months when the following criteria (1) and (2) are met:

1. The patient experienced an inadequate treatment response after a trial of at least 60 days or intolerance to two generic atypical antipsychotics
2. The requested drug is being prescribed for the treatment of depressive episodes associated with Bipolar I disorder

#### **III. QUANTITY LIMIT**

Latuda 20mg, 40mg, 60mg, 120mg tablets have a quantity limit of 1 tablet per day, and Latuda 80mg tablets has a quantity limit of 2 tablets per day.

#### **IV. REFERENCES**

Effective Date: 7/1/2020
Last Reviewed: 4/2020, 3/2021, 2/2022
Scope: Medicaid

1. Latuda (Lurasidone hydrochloride) tablets [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; November 2020.
2. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed April 2020.